MedTrace Logo

Hemp 15 mg & 50 mg Capsule Absorption

NCT05076890 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-02-28

No results posted yet for this study

Summary

This study is intended to investigate the absorption of cannabidiol (CBD) and cannabidiol acid (CBD-A) in plasma from an oral delivery of a single dose of full spectrum hemp extract at two concentrations over a 4-hour timeline.

Conditions

  • Absorption; Chemicals

Interventions

DIETARY_SUPPLEMENT

15 mg/g Full Spectrum Hemp Extract

HPMC capsules containing full spectrum standardized hemp extract in liquid form.

DIETARY_SUPPLEMENT

50 mg/g Full Spectrum Hemp Extract

HPMC capsules containing full spectrum standardized hemp extract in liquid form.

Sponsors & Collaborators

  • Appalachian College of Pharmacy

    collaborator UNKNOWN

  • Gaia Herbs Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-26
Primary Completion
2022-03-26
Completion
2022-03-26

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05076890 on ClinicalTrials.gov